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Objective: To study whether standard cognitive behavioral therapy (CBT) and a shorter,
interpersonal oriented cognitive behavioral therapy (I-CBT) can improve physical function
and fatigue in patients diagnosed with mild to moderate chronic fatigue syndrome (CFS)
in a multidisciplinary fatigue clinic.
Design: Consecutively 236 participants 18–62 years old meeting the Centre of Decease
Control, CDC 1994 criteria, with a subsample also fulfilling the Canadian criteria for
CFS, were randomly allocated to one of three groups. Two intervention groups received
either 16 weeks of standard CBT or 8 weeks of I-CBT vs. a waiting-list control
group (WLC). Primary outcome was the subscale Physical Function (PF) from SF-36
(0–100). Secondary outcome was amongst others fatigue measured by Chalder Fatigue
Questionnaire (CFQ) (0–33). Outcomes were repeatedly measured up to 52 weeks
from baseline.
Results: The additional effect relative to baseline at post-intervention for SF-36 physical
function was 14.2 (95% CI 7.9–20.4 p < 0.001) points higher for standard CBT and
6.8 (0.5–13.2 p = 0.036) points higher for I-CBT compared with the control group.
The additional effect relative to baseline at post-intervention for fatigue was 5.9 (95%
CI 0.5–10.5 p = 0.03) points lower for standard CBT compared with the control group
but did not differ substantially for I-CBT 4.8 (95% CI −0.4 to 9.9 p = 0.07). The
positive change in physical function persisted at 1-year follow-up for both treatment
groups, and for standard CBT also in fatigue. The two intervention groups did not differ
significantly in self-reported physical function and fatigue at the 1-year follow-up. No
serious adverse reactions were recorded in any of the groups during the trial period.
Gotaas et al. Cognitive Behavioral Therapy for CFS
Interpretation: A 16-week standard, individual CBT intervention improves physical
function and fatigue in CFS outpatients with mild to moderate disease. A shorter 8-week
I-CBT program improves physical function. Both treatments are safe, and the effect
persist 1 year after baseline.
Clinical Trial registration: ClinicalTrials.gov, Identifier: NCT00920777, registered June
15, 2009.
REK-project number: 4.2008.2586, registered April 2, 2008. Funding: The Liaison
Committee for Education, Research and Innovation in Central Norway.
Keywords: CFS, chronic fatigue syndrome, CBT, fatigue, physical function, myalgic encephalitis
INTRODUCTION
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME),
is an illness characterized by unexplained, severe fatigue and post
exertional malaise with additional symptoms including, cognitive
impairment, sleep disturbance, sensory hypersensitivity,
headache, pain in muscles and joints, irritable bowel and
intermittent flu-like symptoms (1–4). The illness severely
impairs the patients‘ daily functioning both socially and in terms
of income acquisition (5).
The terms CFS and ME are often used interchangeably and in
combination, CFS/ME, ME/CFS. Until recently, there has been
no international consensus on whether ME and CFS are separate
conditions or similar enough to belong under an umbrella
term such as CFS/ME (6). In this study CFS means all these
terms, according to the new ICD-11 classification (7). Many
different criteria sets are used to diagnose CFS, such as the
Oxford and Sharpe 1991, CDC 1994, Reeves 2003, Canadian
Consensus Criteria, NICE 2007, the International Consensus
Criteria 2011 (8) and the ‘systemic exertion intolerance disease‘,
SEID criteria 2015 (2, 3). There is no scientific basis to claim
that some criteria are more accurate than others to classify a CFS
phenotype (9, 10). In ICD-10 the code G 93.3 “post viral fatigue
syndrome” and “benign myalgic encephalomyelitis” is used for
the illness, but no criteria are specified (11). The newly published
ICD-11 also adds the term chronic fatigue syndrome (CFS) to
these and codes it 8E49 with the parent “other disorders of the
nervous system” (7).
Due to terminological variations and diagnostic
inconsistencies, it is difficult to assess the prevalence and
incidence rate of CFS in a population. Overall prevalence
estimates worldwide vary from 0.1 to 2.5%, depending on the
diagnostic criteria used (1, 12, 13).
The etiology of CFS is largely unknown. Nevertheless,
several possible predictors and associative mechanisms have
been hypothesized, including various infections, prolonged strain
and physical trauma (14, 15), an autoimmune etiology (16),
as well as leaky gut and microbiome (17). Several molecular
neuro-biological approaches have also been made to explore
the etiology of CFS (18). As of today, there is no known
biomarker to diagnose CFS, and a biopsychosocial model has
been taken into consideration for both understanding, treatment
and rehabilitation (19). Clinical examination and blood tests
are directed toward confirming or excluding other possible
clinical conditions.
According to systematic reviews, individual cognitive
behavior therapy (CBT) and graded exercise therapy (GET)
have until now been the best-documented treatments for mild
to moderate CFS, also in combination, but the effect has been
found to be moderate (20–23). However, some of these studies
have been debated and criticized, due to methodological issues
such as patient selection, inclusion criteria and lack of objective
outcome measures (24). Group CBT therapy has also shown
moderate improvement in CFS-patients (25). However, due
to few randomized studies with varying quality and the use of
different sets of criteria for diagnosing CFS, there is no consensus
whether CBT is an effective and safe treatment for all patients
with CFS (20, 26–28). On the other hand, few adverse effects are
found in CBT treatment. In a reanalysis of three RCTs on CBT
for CFS, it was concluded that patients receiving CBT did not
experience more frequent or more severe symptom deterioration
than untreated patients and that the reported deterioration
during CBT seemed to reflect the natural variation in symptoms
(27). In spite of that, a small review by Twisk et al. have suggested
worsening in patients with CFS after CBT and GET (29). Thus,
the reporting of non-serious adverse events may reflect the
nature of the illness rather than the effect of treatments (30).
This study aims to increase knowledge on whether standard
and interpersonal oriented individual cognitive behavioral
therapy can be an effective treatment for mild and moderate
chronic fatigue syndrome, and whether a presumptive positive
outcome persists in 1 year from baseline. To investigate this
question, we designed a consecutive randomized controlled trial
with a 1-year follow-up to compare a standard CBT and a shorter,
interpersonal CBT (I-CBT) vs. a waiting list control group
(WLC) and assess the possible treatment effect sustainability.
Systematic reviews on treatment and management of chronic
fatigue syndrome have found little evidence concerning the
appropriate duration of follow-up of interventions used in the
management of CFS (31, 32). However, as CFS is a long-term
condition it would be sensible to follow up participants for an
appropriate period. The relapsing nature of CFS suggests that
follow-up should continue for at least 6–12 months after the
intervention period has ended. It is of importance to confirm
that the improvement observed has been due to the intervention
itself and not just to a naturally occurring fluctuation in the
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course of the illness. There are few RCT studies with CBT
for CFS with 1-year follow-up assessments and especially few
if any, with individual CBT and waiting list controls (32–35).
The inclusion criteria, number of patients and length, content
and administration of therapy vary a great deal between the
trials. This has made it a challenge to compare and generalize
the findings. We have not found that any of the existing meta-
analysis on CBT for CFS have examined treatment length as
an important variable. In a Cochrane systematic review from
2008, four studies offered eight or fewer sessions of CBT, and
two studies offered more than eight sessions of CBT (36). A
highly significant difference in effect of similar magnitude was
shown for both CBT groups when compared with usual care.
We hypothesized that both standard CBT and I-CBT would
have statistically significant effects on physical function as the
primary outcome, as well as secondary outcomes e.g., fatigue,
compared with theWLC group in CFS diagnosed with the Centre
of Decease Control, CDC 1994 and Canada criteria (12, 37). We
also hypothesized that there would be no statistically significant
difference in primary and secondary outcomes between standard
CBT and I-CBT. If it turns out to be no significant difference in
outcome after the I-CBT and standard CBT interventions, the
shorter therapy can be a less strenuous and more cost-effective
treatment, as has been studied in other psychotherapy studies
(38). The prospect of a less weary treatment may be of special
importance to patients with CFS and may help make this type of
intervention more accessible. We aimed to assess the effect and
safety of both treatments.
MATERIALS AND METHODS
Study Design and Participants
This study was a consecutive randomized controlled open-label
trial with outcome assessed up to 52 weeks after baseline for
patients meeting the CDC 1994 criteria (37) for CFS.
The trial was registered and approved by the Norwegian
Regional Committee for Medical and Health Research Ethics
(REC Central/NTNU) April 2, 2008, before inclusion of patients.
There was a delay in registration of the trial in Clinical Trials
(June 15, 2009), because the research group was not aware of the
registration requirements at the time. The authors confirm that
all ongoing and related trials for this intervention are registered.
In all, 626 patients with unspecified fatigue referred from their
GP were assessed for eligibility at the CFS/ME clinic at St.
Olav‘s Hospital in Trondheim between October 6, 2008, and
September 12, 2012 (Figure 1). Of the 328 assessed patients
who met the CDC 1994 criteria for CFS, 236 were recruited
and gave their consent to be included in the trial (10 were
included in a pilot study and 82 declined randomization). In
the last year of inclusion, participants were also assessed by
the Canada 2003 criteria (39). A total of 110 of 132 patients
(83.3%) diagnosed in this period were found to meet both the
CDC 1994 and Canada 2003 criteria for CFS. Of these 110
patients, 74 gave their consent to be included in the trial, while 36
declined randomization. Outcome data collection was completed
on September 26, 2013.
Procedure
All referrals to the clinic were screened by an experienced
multidisciplinary team consisting of a doctor (general
practitioner), a clinical psychologist or psychiatrist, a physical
therapist, and a registered nurse. Blood samples were taken from
each patient in accordance with the Norwegian Directorate of
Health’s requirement for assessing patients with suspected CFS
(40), including numerous immunology, serology, and standard
clinical chemical test (See Appendix S5). The tests were primarily
done for the purpose of identifying patients with CFS, but some
of the test results will also be utilized in later articles generated
from this study to answer relevant research questions.
The physical therapist tested the patient’s physical condition,
including an indirect VO2max test, muscle tonus, tender points
and a brief neurological examination. The psychologist or
psychiatrist used a structured interview M.I.N.I (International
neuropsychiatric interview) (41) to assess and evaluate the
patients’ mental health status in addition to a clinical
psychological examination. The physician‘s main task was
to detect specific medical and psychiatric disorders and, in such
cases, refer them to other medical or psychological treatments
(37). Based on the multidisciplinary examination, the team
thereafter decided whether the patient met the CDC 1994 criteria
for CFS, and later also the Canada 2003 Criteria, and thus did
not have any other medical or psychological conditions which
explained their CFS symptoms, including disabling fatigue and
post-exertional malaise (PEM). Patients who did not meet the
CDC 1994 criteria or were pregnant, younger than 18 years or
older than 62 years were excluded. Patients who were unable to
attend hospital outpatient appointments or did not speak fluent
Norwegian were also excluded.
Randomization and Masking
After baseline assessment and having obtained a written consent,
participants were allocated to either one of the two treatment
groups or to the control group by computer-generated sequence,
provided by the Section for Applied Clinical Research (ACR) at
NTNU. Once notified of treatment allocation by the ACR, the
research coordinator informed the participant, first by phone and
later in a letter including practical information and a treatment
plan. The participants started treatment within 3 weeks after
randomization. Participants and therapists could not be masked
to treatment allocation. Both therapist and participant knew
the length and contents of the therapy that was given. The
participants scored the primary and secondary outcomes in
questionnaires. The statistician was masked to treatment groups
when analyzing the outcome data, but the difference in number
of measuring points made total masking a challenge.
Interventions
Cognitive behavioral therapy (CBT) is a form of psychotherapy
with assumed moderate effect for many patients with mild
to moderate CFS (20). Standard CBT, also called “classical,”
“Beckian,” or “second wave” CBT seeks to reduce and eliminate
the symptoms of problems by changing behaviors associated
with “automatic thoughts,” emotions and physical symptoms
(e.g., pain or fatigue) (42). The cognitive behavioral model
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FIGURE 1 | Consort flow chart.
hypothesizes that it is not a situation in and of itself that
determines what people feel and perceive, but rather the way
in which they construe a situation which may influence the
physical symptoms (43, 44).
The 16-week intervention of individual, standard CBT was
given by three trained cognitive therapists at St. Olav’s Hospital,
Trondheim, Norway. The actual therapy manual was based on
previous manuals from similar trials (35, 45), and associated
with the fear avoidance (FA) theory of CFS (46). The FA theory
focuses on the link between cognitive and behavioral responses.
The intervention consisted of 16 weekly sessions plus a booster
session 4 weeks after the 16th session. The following main
elements were included in the intervention: (a) information
and explanation of the CFS symptoms based on contemporary
knowledge on both physical and psychological components, (b)
agreement on goals for the treatment (c) reading of self-help
guides about how to cope with chronic fatigue (d) avoidance of
excessive activity or rest and/or sudden change in activity, (e)
planning of regular, predictable, continuous and graded activity
to prohibit deconditioning, (f) recovering self-confidence and
self-control by starting with a 5-min walk morning and night
followed by gradual development (GET), and (g) standard CBT-
procedures (47). Graded activity is used analogs with “graded
exercise therapy” (GET) in this study, as the activity program
was not primarily traditional sports exercises, but rather gradual
activity exercises anchored to the fear avoidance model (48).
The 8 weeks of individual, interpersonal and personality-
oriented CBT was given by four trained cognitive therapists
at the private health centre Coperio, Trondheim, Norway.
The treatment manual was developed by co-author (TCS).
The intervention consisted of 8 weekly therapy sessions and
a booster session 4 weeks after the eighth session. I-CBT is
a new form of treatment for CFS/ME. Its treatment effects
have thus not been tested before. Since standard CBT has been
shown to have limited effects in previous outcome studies,
it was considered to compare standard CBT with a more
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interpersonal oriented approach. Although the focus of I-CBT
is on more interpersonal issues, it is still the traditional CBT
approach of identifying how they think, feel and behave in
the situation. Moreover, underlying beliefs are identified and
challenged. The treatment was based on a biopsychosocial model
(49) in which elements from interpersonal cognitive therapy
(50) and personality-guided therapy (51) were integrated. It
assumes that treatment must be individualized to match the
prominent personality style of the patient. Four personality
styles were identified: Cautious, achievement oriented, identity
or role confused and disease oriented. The overarching goal of
the treatment was to give the patient insight into own personal
goals and needs, to know their true inner self, and how to
improve their interpersonal relatedness toward others, including
family, friends, work relations and health and welfare authorities.
The following elements were included in the intervention: (a)
information and explanation of the CFS symptoms based on
contemporary knowledge on both physical and psychological
components with specific emphasis on the goals and needs of
the self, its ability to emotion regulate and to actively improve
relationships with others, (b) agreement on long-term goals
related to self-satisfaction and interpersonal functioning rather
than immediate symptom reduction and increase in physical
function, and (c) focus on individualized personality-guided and
interpersonally oriented factors that were assumed to create
painful and difficult experiences to the individual.
The control group was a waiting-list group in which the
participants waited for 16 weeks after baseline before they were
post-scored and then offered 8 weeks of I-CBT outside the
study. The ideal would have been a control period up to 1
year without intervention, but this was not possible due to
ethical considerations.
Supervision/internal validity CBT was delivered by clinical
psychologists and one psychiatrist. Supervision in both I-CBT
(TCS) and standard CBT (EAF) was given to the therapists as a
group once a month, or individually if required. All treatment
sessions for standard CBT were audio-recorded to make quality
assurance and CBT guidance possible. Adequate use of standard
CBT was quality assured by an independent observer using the
CTACS quality assuring instrument (52). All treatment sessions
for I-CBT were recorded on tape to make quality assurance by
the head professional advisor possible. The therapists in both
treatment groups registered the number of therapy sessions
attended for each patient, active withdrawals from treatment, and
dropouts from follow-up. Specialist medical care physicians from
the CFS outpatient clinic were available to the patients if needed
throughout the study period.
Assessments
The primary outcome measure in this study was the SF-36
version 2 physical function subscale, one of eight subscales
(53), presented as a so called “mean difference, additional effect
relative to baseline at post- intervention.” In SF-36, raw score
data are converted to a scale range of 0–100, where the highest
score reflects best self-rated function. An important secondary
outcome was global fatigue measured by the Chalder fatigue
questionnaire (54). In the Chalder fatigue questionnaire, there
is a Likert scoring 0, 1, 2, 3 on 11 items; range 0–33, where
the highest score reflects high fatigue. Both the primary and
secondary outcome measures are valid and reliable and have
been used in numerous trials worldwide, including CFS studies
(21, 36, 54). Other secondary outcomes than fatigue were the
remaining SF-36 measures/subscales of bodily pain; role physical
and general health, vitality, social functioning, role emotional
and mental health. The first three subscales reflect the patient‘s
physical health, while the last four reflect the mental health. All
measures were self-rated by the participants. The objective tests,
such as an indirect VO2max test, muscle tonus, muscular tender
points and a brief neurological examination were obtained for
clinical use and later articles.
16-Week CBT
Assessments were made at baseline (0 weeks), just after
randomization, at mid-therapy (13 weeks), post therapy (20
weeks/post-intervention), 4 weeks after booster (29 weeks), and
1 year after baseline (52 weeks).
Eight-Weeks I-CBT
Assessments were made at baseline (0 weeks), just after
randomization, post therapy (12 weeks), 4 weeks after booster (21
weeks/post-intervention), and 1 year after baseline (52 weeks).
Waiting-List Control Group
Assessments were made at baseline (0 weeks), just after
randomization, halfway through the waiting period (10
weeks), and at the end of the 16 weeks waiting period
(18 weeks/post-intervention).
Safety Monitoring: Adverse Reactions and Adverse
Events (Harms)
For safety monitoring, we registered adverse events, adverse
reaction to trial treatment, and active withdrawal from treatment.
Adverse events and adverse reactions were defined as any
negative clinical symptom change, disorder, or disease occurring
during the study period whether related to the treatment or not.
The participant-rated Clinical Global Impression scale was used
to assess change in overall health during the trial period (Clinical
Global Impressions Scale (CGI-ECDEU, 1976; CIPS, 1986) (55).
The therapists also recorded events, if any, in the participants’
journal. The therapists also reported to the study coordinator
and the medical director of the study. In need of further medical
assessment, the patients were instructed to contact their GP or
local hospital.
Statistical Analysis
We calculated sample size assuming a mean change in SF-36
physical function subscale score of 10, 5, and 0 from baseline
of, respectively, short I-CBT, standard CBT, and WLC group,
a ‘within cell‘ standard deviation (SD) on 15 and a correlation
between baseline and post-intervention on 0.3 (r-squared on 0.1).
For a two-sided test with 5% significance level and 80% power, we
calculated that we needed 40 patients in each group, 120 in total.
Assuming a maximum drop-out level of 25%, we calculated that
we needed an additional number of 18 patients in each group, 174
patients in total. A mean change in SF-36 physical function score
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of 10, 10, and 0 for standard, short andWLC groups, respectively,
would increase power to 90%.
A clinically or minimal important difference (MID) was
defined as an improvement of >10 points for the “mean
difference, additional effect relative to baseline at post-
intervention” or a mean score in SF-36 physical function of
>75 post-intervention (56, 57). Norwegian reference values for
physical function in SF-36 exists (58), but are calculated with a
different edition of SF-36 (version 1) than the one used in our
study (i.e. version 2). As an example of a similar population to
compare with, the SF-36 physical function version 2 score for
the UK working age population is 84, with a SD of 24. Thus,
a SF-36 score equal to or above the mean minus 1 SD will be
considered in the normal range (score of 60 or more) (56). That
would make a SF-36 physical function score of 75 or more within
normal range (56).
For the Chalder fatigue scale, a MID was not pre-defined,
but 0.5 of the SD of these measures at baseline is described in
literature (57, 59). In our study, this equates to 3 points for
Chalder fatigue scale (rounded up from 2.64). Normal range for
fatigue was defined as less than the mean plus 1 SD scores of
the general Norwegian population of 12.2 (+3.9) (60). That is
equivalent to a fatigue score of 16.1 or less.
All patients who were enrolled and randomly allocated to
treatment were included in the analysis and analyzed in the
groups to which they were randomized (intention to treat/ITT)
except the patients excluded for becoming pregnant during
the trial (n = 4). Due to repeated measures of outcomes, we
used a multilevel linear regression model with random slopes
in STATA 11 for Windows (Stata Corp., College Station, TX).
This method uses all available information during follow-up
and is less susceptible to bias from missing responses under the
assumption of missing at random. Each follow-up time-point
was added to the model as a dummy variable (i.e., 10–13 weeks,
18–21 weeks, 52 weeks and the baseline as a reference). To
assess differences between intervention groups and the waiting-
list group during follow-up, interaction terms between the group
allocation and each registration time-point were included in
the model. We also tested a model with only participants with
complete registrations of the outcome on all follow-up time
points (i.e., “per protocol,” not presented in figures or tables).
To assess outcome clustering at the patient level, we estimated
an intraclass correlation coefficient (ICC) (61).
Role of the Funding Source
The funding source, The Liaison Committee for Education,
Research and Innovation in Central Norway, had no role in the
study design, data collection, data analysis, data interpretation,
or writing of this report/article. All the named authors had
access to the anonymised data and commented on drafts during
the process leading to the final report. The research group had
the final responsibility for the decision to submit the report
for publication.
Ethics
The study is approved by the Norwegian Regional Committee
for Medical and Health Research Ethics (REC Central/NTNU)
in Norway, no 4.2008.2586. All patients gave written consent
to participate in the study. Patients randomized to the control
group were offered 8 weeks of individual I-CBT after the
predefined waiting period of 16 weeks was completed. The
ideal would be to have a control period up to 1 year after
baseline without intervention, but this was not possible due to
ethical considerations.
RESULTS
Of the 626 patients assessed for eligibility, 581 (93%) completed
medical and psychological examination, while 45 (7%) patients
did not start or complete the assessment. Thereafter 253 (40%)
patients were excluded for the following various reasons: Patients
with fatigue, but who did not meet the CDC 1994 criteria
for CFS numbered 154 (24%). Respectively, 52 (8%) and 40
(6%) patients were excluded because of somatic and psychiatric
disorder. Seven patients did not have fatigue and where thus mis-
referred. That left 328 (52%) assessed patients who met the CDC
1994 criteria for CFS, and of these 236 (72%) were recruited to the
study (Figure 1). One-way analysis of variance between groups
(ANOVA) show that patients’ characteristics at baseline were
balanced between the intervention groups (physical function SF-
36 p= 0.919, age p= 0.055, fatigue p= 0.718, HADS depression
p = 0.474, HADS anxiety p = 0.811 and duration of illness p
= 0.087). There were no statistically significant differences at
baseline between dropouts and non-dropouts (physical function
SF-36 p = 0.527, age p = 0.210, fatigue p = 0.861, HADS
depression p =0.750, HADS anxiety p = 0.656, and duration of
illness p= 0.086).
Differences for categorical variables, tested with Chi-squares
show that there was a higher percentage of women in the
standard group than the I-CBT group p < 0.05, but no
significant difference in years of education p > 0.05 (Table 1).
TABLE 1 | Demographic and clinical characteristics of the participants at baseline.
I-CBT 8 CBT16 WLC
(n = 76) (n = 76) (n = 78)
Mean age (SD) 37 (11) 37(11) 32 (10)
Number female n (%)a 53 (70) 69 (91) 67 (84)
Education bachelor or
higher n (%)
24 (32) 28 (37) 20 (25)
Mean duration of illness
in years (range)
4.5 (0.5–14) 5.3 (0.8–13) 4.6 (0.5–13)
Mean HADS
depression score (SD)
6.6 (4.1) 5.9 (3.6) 6.6 (3.8)
Mean HADS anxiety
score (SD)
6.7 (3.4) 6.8 (3.6) 7.1 (4.1)
HADS-A and HADS-D, Hospital Anxiety and Depression Scale (range 0–21, where 21
is maximum).
aDifferences n (%) for categorical variables, tested with Chi-squares: Number female,
I-CBT vs. standard CBT P < 0.05. There were no other statistically significant differences
between the groups.
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All participants identified racially as white. In the last year of
inclusion, the patients were classified according to both the CDC
1994 and Canada 2003 criteria for CFS, and 110 of 132 patients
(83.3%) were found tomeet both the CDC 1994 and Canada 2003
criteria. Of these 110 patients, 74 were included in the trial, 26
declined randomization. There were no statistically significant
differences in baseline characteristics between the patients who
met both sets of criteria compared to those who were classified
only according to the CDC 1994 criteria (physical function SF-
36 p = 0.236, fatigue p = 0.705, HADS depression p = 0.202
and HADS anxiety p= 0.891). There were neither no statistically
significant differences in physical function SF-36 p = 0.291
scores, HADS depression p = 0.254, HADS anxiety p = 0.254
or fatigue p = 0.521 scores when comparing the groups later
at 20 weeks from baseline. Regardless, the reported anxiety and
depression symptom levels were low, and neither of the groups
scored a mean level of anxiety or depression over a cut-off point
of >8/21 in HADS at baseline (62).
Dropouts
Twenty (8.5%) participants dropped out just after randomization
and had only registered baseline data. Thereafter, 21 (9%)
participants dropped out during treatment. There was a variation
in drop-out frequency between the study groups. In the 8-
week I-CBT group, five of 78 (6%) patients dropped out during
treatment due to fatigue (n = 1), lack of motivation for the
treatment (n= 2), and long distance to treatment centre (n= 2).
In the 16-week CBT group, 16 of 78 (20.5%) participants dropped
out during treatment due to fatigue (n = 3), poor economy (n
= 2), psychosocial strain (n = 2), long distance to treatment
centre (n = 2), lack of motivation for the treatment (n = 4),
change of therapist (n = 1), current infection (n = 1), and need
of further psychiatric evaluation (n = 1). Poor economy in this
context means that the participants could not afford to pay for
transport to the clinic and therefore could not attend therapy
sessions. All baseline data and outcomes registered were analyzed
for all three groups.
Primary Outcome
Standard CBT participants reported a statistically significant
increase in their physical function compared to the WL control
group, and reached a mean additional effect relative to baseline at
post-intervention of 14.2 points, which exceeded the predefined
MID improvement number of >10 (57). Correspondingly, the I-
CBT reached a statistically significant additional effect relative
to baseline at post-intervention of 6.8 points compared to the
WLC-group. At 1-year follow-up, paired t-tests show that both
standard CBT [diff. 0.4 p = 0.35 (95%CI −1.5 to 2.3)] and
I-CBT [diff. 3.2 p = 0.056 (95% CI −0.1 to 6.5)] groups
revealed an unchanged, positive effect on physical function from
post-intervention. Between-groups analyses regarding physical
function found no significant differences between the treatment
groups (95% CI −10.1 to 2.1 p = 0.20) at the 1-year follow-up
(Table 2 and Figure 2).
Secondary Outcomes
Chalder Fatigue Questionnaire
Participants in both treatment groups reported less fatigue
than the control group and exceeded the defined MID on 3.0
points reduction in fatigue post-intervention 20 weeks from
baseline (post-intervention). The mean additional effect relative
to baseline for fatigue at post- intervention was 5.9 (statistically
significant) and 4.8 (not statistically significant) points lower
compared to WLC for standard CBT and I-CBT, respectively
FIGURE 2 | Primary outcome, physical function SF-36 up to 52 weeks.
TABLE 2 | Primary outcome data: physical function score (SF-36).
I-CBT 8 CBT 16 WLC
Physical function score SF-36
Baseline 53.1 (48.5–57.6) 54.0 (49.6–58.4) 54.8 (50.5–59.1)
Post-intervention* 62.9 (58.0–67.9) 71.2 (66.3–76.1) 57.9 (53.2–62.5)





6.8 (0.5–13.2) p = 0.036 14.2 (7.9–20.4) p < 0.001
Table data show mean scores at three timepoints in addition to mean difference, additional effect relative to baseline post-intervention with a 95% CI. SF-36 (0–100), higher score; fewer
symptoms, better function. *Post-intervention: (I-CBT 8: 21 weeks from baseline. CBT 16: 20 weeks from baseline. WLC 18 weeks from baseline). Follow-up: (52 weeks from baseline).
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(Table 3 and Figure 3). I-CBT did not differ substantially from
WLC post-intervention (95% CI −0.4 to 9.9 p = 0.07), however,
the between-groups analyses showed no significant mean score
differences for fatigue at the 1-year follow-up (95% CI −2.8 to
2.1 p= 0.8). Eventually, paired t-tests showed that both standard
CBT [diff. 0.4 (95% CI −1.5 to 2.3 p = 0.68)] and I-CBT [diff.
−1.4 (95% CI −3.0 to 0.2 p = 0.0823)] revealed a sustained
reduction in fatigue from post-intervention to 1 year follow up.
Compared to Norm Scores
At post-intervention, 50% of the standard CBT group and 40%
of the I-CBT group reached a predefined SF-36 physical function
score of 75 points or more at post-intervention, compared to only
20% in the WLC group (57). Furthermore, 31% of the patients in
the standard CBT group, 19% of the patients in the I-CBT group
and 10% of the patients in the WLC- group reported normal
fatigue scores related to the Norwegian population at the end of
the waiting period (a fatigue score of 16.1 or less) (60).
SF-36 Sub-dimensions
For the standard CBT group, there were statistically significant
positive changes in five of the seven remaining subdimensions
for the SF-36 post-intervention scores (i.e., mental health, bodily
pain, role physical, social functioning and vitality) compared to
the control group. The most profound improvements were in the
“role physical,” “social function,” and “vitality” subdimensions.
There were no statistically significant changes in “general health
and role emotional” compared toWLC. Eventually, there were no
statistically significant changes in any of the remaining seven SF-
36 subdimensions for the I-CBT group compared to the control
group (Table 4).
Clinical Global Impression Scale and
Adverse Events
More patients rated themselves as “much better” or “very
much better” in overall health measured by the Clinical Global
Impression Scale (CGI) after both the standard CBT and I-
CBT interventions compared to the control group. At post-
intervention, 33 and 26% in the standard CBT vs. I-CBT group,
respectively, rated themselves as “much better” or “very much
better” in overall health compared to 8% in the WLC group. A
minority (< 5% in each group) rated themselves as “worse” or
“very much worse,” but this did not differ substantially between
the three groups at post-intervention (Table 5). The registered
adverse events were increased fatigue and worsening of other
existing CFS such as nausea, headache and pain in muscles
and joints.
FIGURE 3 | Secondary outcome, Fatigue (CFQ) up to 52 weeks.
TABLE 4 | Secondary outcome data: SF-36 subscales.
I-CBT 8 CBT 16
Mental health 3.6 (−1.9 to 9.2) 6.9 (1.3–12.3)
General health 6.5 (−0.1 to 13.0) 5.2 (−1.5 to 11.4)
Role emotional −3.5 (−14.1 to 7.1) 2.1 (−9.9 to 11.1)
Bodily pain 1.8 (−5.6 to 9.1) 8.6 (1.4–15.8)
Role physical 7.2 (−2.3 to 15.6) 16.5 (7.6–25.4)
Social functioning 6.3 (−4.3 to 16.8) 22.7 (12.0–32.8)
Vitality 6.1 (−0.8 to 13.0) 13.1 (6.3–19.3)
Table data show mean difference, additional effect relative to baseline post-intervention
with a 95% CI. SF-36 (0–100), higher score; fewer symptoms, better function. (I-CBT 8:
21 weeks from baseline. CBT 16: 20 weeks from baseline. WLC 18 weeks from baseline).
Statistically significant findings are highlighted.
TABLE 3 | Secondary outcome data: fatigue score (CFQ).
I-CBT 8 CBT 16 WLC
Fatigue score
Baseline 25.2 (23.9–26.4) 25.3 (24.2–26.5) 25.8 (24.7–27.0)
Post-intervention* 20.7 (19.1–22.4) 18.7 (17.1–20.4) 24.1 (22.6–25.7)





4.8 (−0.4 to 9.9) p = 0.07 5.9 (0.5–10.5) p = 0.03
Data are mean scores and mean difference, additional effect relative to baseline post intervention with a 95% CI. Chalder Fatigue Questionnaire (0–33), lower score, fewer symptoms,
better function. *Post-intervention: (I-CBT 8: 21 weeks from baseline. CBT 16: 20 weeks from baseline. WLC 18 weeks from baseline). Follow-up: (52 weeks from baseline).
Frontiers in Psychiatry | www.frontiersin.org 8 April 2021 | Volume 12 | Article 580924
Gotaas et al. Cognitive Behavioral Therapy for CFS
TABLE 5 | Participant-rated clinical global impression of change in overall
health (CGI).
I-CBT 8 CBT 16 WLC
Post-intervention*
Positive change 15 (26%) 17 (33%) 5 (8%)
Minimum change 40 (71%) 34 (65%) 54 (87%)
Negative change 2 (3%) 1 (2%) 3 (5%)
1-year follow-up
Positive change 17 (30%) 11 (23%)
Minimum change 37 (65%) 32 (67%)
Negative change 3 (5%) 5 (10%)
Odds ratio (positive change









Data are n (%) or odds ratio (95% CI). Positive change was defined as “very much better”
or “much better.” Minimum change was defined as “a little better,” “no change,” or “a
little worse.” Negative change was defined as “much worse” or “very much worse.”
*Comparisons made at “post-intervention”: (I-CBT 8: 21 weeks from baseline. CBT 16:
20 weeks from baseline. WLC: 18 weeks from baseline).
DISCUSSION
Participants who received either 16 weeks of standard CBT with
graded activity/exercise or 8 weeks of interpersonal CBT reported
improved physical function post-intervention compared to a
waiting list control group. The standard CBT participants also
perceived less fatigue post- treatment. The positive effect of these
statistically significant findings sustained for 1 year. The WLC
group was not scored at 1-year follow-up. We discussed the
option to have outcomes measured at 12 months also for the
WLC group, but decided not to because they all received 8 weeks
of I-CBT immediately after the end of the waiting period due
to ethical considerations The standard CBT improved most of
the secondary outcomes in contrast to I-CBT and WLC. Our
findings are consistent with other CBT-treatment trials involving
patients diagnosed with mild to moderate CFS, which have
shown clinical important improvements in both self-reported
physical function and fatigue post-intervention (20, 21). For the
standard CBT intervention, the reintroduction to activity was
graded and systematic, which also implied a tailored plan of
escalation based on each patient’s individual level of physical
function measured at baseline. An individualized plan with focus
on graded, systematic escalation of activity may explain some
of the positive effect for the physical function. Our findings are
supported by previous studies which have suggested that both
CBT and GET can improve physical function and fatigue in some
patients diagnosed with mild to moderate CFS (26). In I-CBT the
goal was to resume a normal level of activity without a graded or
systematic approach. Despite the different approach to activity,
a general focus on being active in both treatment groups could
explain the positive and sustained effect in physical function for
both groups at the 1-year follow-up. Forty-eight percent of the
participants had a SF-36 physical function mean score of 75 or
more at 1-year follow-up. For fatigue, 35% of the participants
were in normal range at 1-year follow-up compared to reference
values for the Norwegian population (58).
Both treatments were well-tolerated. According to the CGI
measures, very few rated themselves as ‘worse or ‘very much
worse‘ post-intervention (n= 1–2, i.e. 2–3%). Furthermore, their
experiences did not vary between the groups including the WLC
group. In contrast, 33% in the standard CBT group, 26% in the
I-CBT group and only 8% in the control group reported to be
“much better or very much better” post-intervention. At the 1-
year follow-up, as many as 23% in the standard CBT group and
30% in the I-CBT group rated themselves as “much better or very
much better” in overall health.
The effectiveness of cognitive behavioral therapy does not
imply that CFS is psychological in nature. Before inclusion
the patients were assessed by a psychologist or psychiatrist to
rule out any psychiatric disorder as a cause of fatigue and
other symptoms. The clinical examination and the HADS-
scores showed that symptoms of anxiety and depression were
generally low in these patients throughout the trial period.
Based on this knowledge, one could assume that the SF-36
PF and fatigue outcome effects were not caused by changes in
psychological variables.
The differences in effect on physical function and the other
SF-36 subdimensions between the groups, could be interpreted
as a positive tendency in favor of standard CBT, even though
they were not evident in between group analysis at 1-year
follow up. The effect differences between the CBT and I-CBT
interventions at post-intervention could be explained by a time
dosage-response effect, alternatively as a consequence of different
contents in the two therapy modes. At post-intervention, the
standard CBT group had received 16 sessions of therapy, while
the I-CBT group had got nine, including one booster session.
Leveling of the results over time to a non-significant difference
in both primary and secondary outcomes between the treatment
groups at 1-year follow-up, indicate that CBT has a sustained
positive effect on physical function and fatigue in these patients in
general, regardless of differences in length and content of therapy.
The higher dropout rate in the standard CBT group compared to
the I-CBT group (20.5 vs. 6%) may also be due to either duration
of, or differences in content of therapy. However, in this trial,
regardless of cause, the patients show a lower dropout rate for I-
CBT than standard CBT, which may indicate a better compliance
in I-CBT. However, since we did not measure compliance explicit
in this study, it is just a hypothesis. Nevertheless, analyses showed
no statistically significant differences in baseline characteristics
when comparing dropouts to non-dropouts. No serious adverse
events or reactions were recorded in any of the groups. This
suggests that CBT, if delivered as described in the manuals by
similarly qualified and trained clinicians, is a well-tolerated and
safe treatment for patients with mild to moderate CFS. The
finding that many of our participants reported “minimal change”
at post-intervention and at the 1-year follow-up suggests that
treatment effects can differ between subgroups. It would be of
interest to explore whether special characteristics can be found
in patients who benefit from CBT, and thus indicate who should
be referred to therapy with a prospect of improvement. This is
also thermalized in other studies (63).
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Our findings were strengthened by the study design
(randomized, controlled trial, RCT) the relatively high number of
participants, the standardized multi-disciplinary assessment by
trained physicians, psychologists and physical therapists before
inclusion, the use of manual-defined CBT provided by competent
clinicians, the thorough blood-test examinations as well as the use
of CTACS as a quality-assuring instrument.
Our trial also had some limitations: There was a delay in
registration in Clinical Trials, because the research group was not
aware of the registration requirements at the time. The inclusion
of patients started 5 months after registration and approval
from the Regional Ethics Committee. We excluded patients who
were unable to attend the hospital out-patient clinic, which
meant that only out-patients with mild to moderate CFS were
included. We ended up with ∼13% missing data after 8.5% of
the patients dropped out just after randomization and 9% during
treatment. The drop-out rate is similar to other CBT studies for
CFS (22). Missing at random is an assumption not possible to
test directly and there was some evidence of higher number of
missing responses for the standard CBT due to the larger number
of dropouts compared to the other groups. Another limitation
was that the intervention groups received different types of
CBT regarding both duration and therapeutic content, which
made it difficult to make a precise chronologic comparison.
The difference in length of therapy also made it difficult to
achieve true masking to treatment allocation of the statistician
undertaking the analysis of primary outcomes. The intervention
groups did not have the same time assessment points after
randomization. Hence, measurements and comparisons were not
made at the same number of weeks. Given the chronic nature
of CFS, a difference of a week or two is unlikely to make
a difference to the analyses, but it would have been optimal
to compare the groups at the exact same number of weeks
throughout the entire trial. Also, due to ethical considerations,
we were not allowed to follow the WCL group for more than 18
weeks post baseline before they were offered therapy. Thus, the
WLC group was not scored at 1-year follow-up. We considered
to measure outcomes at 12 months also for the WLC group
but decided not to because they all received 8 weeks of I-CBT
immediately after the end of the waiting period, which would
contaminate the group. There is limited knowledge of the natural
time variation for CFS patients participating in clinical trials,
but other studies with long term-follow-up after CBT for CFS
show fairly sustained positive effects (20, 64). Both the primary
and secondary outcomes were subjective in this study i.e., rated
by the participants impressions. The lack of established specific
and sensitive biomarkers limits the potentials for valid objective
endpoints. Nevertheless, obtained objective tests, such as e.g.,
indirect VO2 max scores will be presented in later articles.
CONCLUSION
The findings of this study suggest that both standard CBT
and the shorter I-CBT-intervention, individually delivered, are
safe therapies which improve physical function in patients with
mild to moderate CFS. Standard CBT also cause positive effects
on fatigue. The positive effects sustained for at least 1 year.
Thus, patients with mild and moderate chronic fatigue syndrome
diagnosed according to the CDC and Canadian Consensus
Criteria should be offered individual CBT with a prospect of
improved physical function and a safe fatigue symptom relief,
even though anxiety and depression symptom scores are normal.
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